CASI Pharmaceuticals (CASIF) Long-Term Investments (2021 - 2025)

CASI Pharmaceuticals (CASIF) has 5 years of Long-Term Investments data on file, last reported at $1.7 million in Q4 2025.

• Quarterly Long-Term Investments fell 10.3% year-over-year to $1.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.7 million (down 10.3% YoY) and the FY2025 annual result came in at $1.7 million, down 10.3% from the prior year.
• Long-Term Investments steadied at $1.7 million in Q4 2025, from $1.7 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $3.6 billion in Q2 2023 to a low of $1.7 million in Q1 2024.
• A 5-year average of $823.8 million and a median of $4.4 million in 2022 frame the typical range for Long-Term Investments.
• The widest YoY moves for Long-Term Investments: up 113490.5% in 2025, down 99.9% in 2025.
• Tracing CASIF's Long-Term Investments over 5 years: stood at $40.1 million in 2021, then slumped by 89.04% to $4.4 million in 2022, then jumped by 38235.61% to $1.7 billion in 2023, then slumped by 99.89% to $1.9 million in 2024, then fell by 10.3% to $1.7 million in 2025.
• The last three Long-Term Investments figures came in at $1.7 million (Q4 2025), $1.7 million (Q3 2025), and $1.7 million (Q2 2025), per Business Quant data.